Immunotherapy with anti-CD20 compounds

被引：15

作者：

von Schilling, C ^{[1
]}

机构：

[1] Tech Univ Munich, Klinikum Rechts Isar, Med Klin 3, D-81675 Munich, Germany

来源：

SEMINARS IN CANCER BIOLOGY | 2003年 / 13卷 / 03期

关键词：

B-cell lymphoma; CD20; clinical trials; monoclonal antibody;

D O I：

10.1016/S1044-579X(03)00018-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The B-cell surface antigen CD20 is currently the prime target for near-selective treatment of mature B-cell malignancies and a range of reactive B-cell associated disorders (including virus-associated lymphoproliferation or autoimmune conditions). CD20 is strongly and homogeneously expressed on the majority of mature B-cell neoplasms except chronic lymphocytic leukaemia cells, and on all mature reactive B-cells. This review will summarise the modes of action of various reagents targeting CD20. Treatment results following their use in single and combination therapy for B-cell disorders are reviewed. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：211 / 222

页数：12

共 184 条

[1]

Alas S, 2000, ANTICANCER RES, V20, P2961

[2]

Alas S, 2001, CANCER RES, V61, P5137

[3]

Alas S, 2002, CLIN CANCER RES, V8, P836

[4] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma [J].

Anderson, DR ;

GrilloLopez, A ;

Varns, C ;

Chambers, KS ;

Hanna, N .

BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) :705-708

[5] The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].

Anolik, JH ;

Campbell, D ;

Felgar, RE ;

Young, F ;

Sanz, I ;

Rosenblatt, J ;

Looney, RJ .

ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459

[6] Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma [J].

Ansell, SM ;

Witzig, TE ;

Kurtin, PJ ;

Sloan, JA ;

Jelinek, DF ;

Howell, KG ;

Markovic, SN ;

Habermann, TM ;

Klee, GG ;

Atherton, PJ ;

Erlichman, C .

BLOOD, 2002, 99 (01) :67-74

[7] RETRACTED: High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support - Results of a pilot study (Retracted Article) [J].

Behr, TM ;

Griesinger, F ;

Riggert, J ;

Gratz, S ;

Béhé, M ;

Kaufmann, CC ;

Wörmann, B ;

Brittinger, G ;

Becker, W .

CANCER, 2002, 94 (04) :1363-1372

[8] Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species [J].

Bellosillo, B ;

Villamor, N ;

López-Guillermo, A ;

Marcé, S ;

Esteve, J ;

Campo, E ;

Colomer, D ;

Montserrat, E .

BLOOD, 2001, 98 (09) :2771-2777

[9]

Bennett JM, 2001, BLOOD, V98, p335A

[10] Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma [J].

Berinstein, NL ;

Grillo-Lopez, AJ ;

White, CA ;

Bence-Bruckler, I ;

Maloney, D ;

Czuczman, M ;

Green, D ;

Rosenberg, J ;

McLaughlin, P ;

Shen, D .

ANNALS OF ONCOLOGY, 1998, 9 (09) :995-1001

← 1 2 3 4 5 6 7 8 9 10 →